The Legal Barrier: What the Law Actually Says

Medicare cannot negotiate drug prices for most medications because federal law forbids it. Specifically, the Medicare Modernization Act of 2003 included a provision that bars Medicare from using its purchasing power to bargain directly with pharmaceutical manufacturers. The law requires Medicare to pay the price the drug maker sets, with limited exceptions.

This restriction applies to Part D (prescription drug coverage) and most Part B drugs. The only drugs Medicare can negotiate on are a small number of high-cost medications covered under Part B — and even that power is new. A 2023 law change allowed Medicare to negotiate prices on ten specific drugs starting in 2024, and that number will grow slowly over time. But for the vast majority of prescriptions, the ban remains in place.

The reasoning behind the 2003 law was that allowing Medicare to negotiate might discourage pharmaceutical companies from developing new drugs. Supporters of the ban argued that drug makers need high prices to fund research. Opponents argued then — and still argue — that other countries negotiate successfully without killing innovation.

Key Takeaways

  • Federal law from 2003 prohibits Medicare from negotiating prices on most drugs, requiring Medicare to pay whatever price manufacturers set.
  • A 2023 change allows Medicare to negotiate on a small, slowly growing list of high-cost drugs — ten drugs in 2024, expanding to more over time.
  • Part D plans (private insurers) can negotiate on your behalf, but they work within the prices manufacturers offer, not against a legal ban.
  • Other countries like Canada and Germany negotiate drug prices directly with manufacturers, but U.S. law has prevented Medicare from doing the same.
  • If you pay high out-of-pocket costs for a drug, manufacturer information programs and Part D extra help programs may lower what you owe.

How the 2003 Law Changed What Medicare Can Do

When Congress created the Medicare prescription drug benefit in 2003, it wrote the law in a way that gave drug manufacturers control over pricing. Medicare was required to cover drugs that manufacturers offered, at the prices manufacturers set. This was different from how Medicare handles hospital and doctor payments — those are negotiated between Medicare and providers.

The law also prohibited the federal government from using its size as leverage. Even though Medicare covers roughly 45 million people, the law said Medicare could not threaten to exclude a drug from coverage in order to push the price down. Private insurance companies that run Part D plans could negotiate, but they operated within the same constraint: manufacturers could straightforward refuse to participate in a plan if the price offer was too low.

This setup meant that Part D plans compete on service and coverage, not on the underlying drug price. A plan might offer better copays or a wider network, but the actual price paid to the manufacturer stays roughly the same across plans.

The 2023 Change: What Medicare Can Now Negotiate

In August 2023, Congress passed the Inflation Reduction Act, which gave Medicare limited power to negotiate drug prices for the first time. Starting in 2024, Medicare can negotiate on ten high-cost drugs covered under Part B and Part D. The list includes drugs for conditions like diabetes, heart failure, and blood clots.

The negotiation process is slow and narrow. Medicare can only negotiate on drugs that have been on the market for at least nine years (or eleven years for biologics). The negotiated price takes effect the following year, so a drug negotiated in 2024 would have the new price in 2025. Manufacturers can refuse to negotiate, but if they do, Medicare can remove the drug from coverage — a real consequence that gives Medicare actual leverage for the first time.

The list grows over time. By 2026, Medicare will be able to negotiate on up to 20 drugs. By 2029, that number reaches 60. But this is still a tiny fraction of the thousands of drugs Medicare covers. For most prescriptions, the 2003 ban remains the law.

Why Part D Plans Cannot Negotiate Lower Prices

Part D is run by private insurance companies, not by Medicare directly. You might think these insurers would have leverage to negotiate, since they cover millions of people. But they operate under the same legal constraint as Medicare: manufacturers can refuse to work with a plan if the price offer is too low.

What Part D plans actually do is manage which drugs are covered and at what cost to you. They create formularies — lists of covered drugs organized by tier. A drug on tier 1 might cost you $10 at the pharmacy, while the same drug on tier 3 might cost you $50. The plan negotiates the copay structure with you, not the underlying price with the manufacturer.

Plans also use prior authorization and step therapy to manage costs. They might require you to try a cheaper drug first before covering an expensive one. But they cannot force the manufacturer to lower the price itself. The manufacturer sets the price; the plan decides whether to cover it and at what tier.

How Other Countries Negotiate and Why the U.S. Does Not

Canada, Germany, Australia, and most other developed countries negotiate drug prices directly with manufacturers. A government agency in each country reviews the drug's effectiveness, compares it to existing treatments, and offers a price. If the manufacturer refuses, the drug is not covered in that country's system.

This works because those countries have single-payer or heavily regulated systems where one buyer (the government) controls access to the entire market. A manufacturer cannot sell the drug in Canada without accepting Canada's price. The same applies in Germany or Australia.

The United States has a fragmented system. Medicare is one buyer, but it is not the only one. Private insurers, Medicaid, the Veterans Health Administration, and uninsured patients all buy drugs at different prices. A manufacturer can refuse Medicare's offer and still sell to private insurers at a higher price. This fragmentation is why the 2003 law was written the way it was — to prevent Medicare from being the only buyer and forcing prices down across the entire market.

Whether this fragmentation is good policy is debated. Supporters of the current system say it protects innovation. Critics say it means Americans pay more for the same drugs than patients in other countries.

What You Can Do If Your Drug Costs Are High

If you are paying high out-of-pocket costs for a prescription, several programs may help, even though Medicare itself cannot negotiate the price down.

Manufacturer information programs offer free or reduced-cost drugs directly from the drug maker. Most major manufacturers have these programs. You explore through the manufacturer's website or by calling the number on the drug's packaging. Income limits vary, but many programs cover people with incomes up to 200 or 300 percent of the federal poverty level.

Part D Extra Help is a federal program that lowers your copays and deductibles if your income is below 150 percent of the federal poverty level. You explore through Social Security or your local Medicaid office. This program can cut your out-of-pocket costs significantly.

Patient information organizations like NeedyMeds and RxAssist maintain databases of programs that help pay for specific drugs. These are free resources that connect you to manufacturer programs, nonprofit information, and other funding sources.

Your Part D plan may also have a coverage exception process. If a drug is not on your plan's formulary, you can ask your doctor to request an exception. The plan may approve it, sometimes with a higher copay. This is not price negotiation, but it can get you access to the drug you need.

Frequently Asked Questions

Does Medicare negotiate any drug prices at all?

Yes, but only for a small list. Starting in 2024, Medicare can negotiate prices on ten high-cost drugs covered under Part B and Part D. This list grows to 20 drugs by 2026 and 60 by 2029. For all other drugs, the 2003 law still applies and Medicare pays the manufacturer's price.

Why did Congress pass a law preventing Medicare from negotiating in 2003?

The stated reason was to encourage drug innovation. Supporters argued that high prices fund research and development. The law was passed with support from both parties and the pharmaceutical industry. Whether the law actually achieved this goal is disputed by economists and policy experts.

If my Part D plan covers a drug, why does it still cost so much?

Your plan covers the drug, but the manufacturer sets the price. Your plan decides what tier the drug is on and what you pay as a copay. The plan cannot force the manufacturer to lower the price itself. If your copay is high, ask your doctor about generic alternatives or check whether you may have access to for manufacturer information or Part D Extra Help.

Can I buy the same drug cheaper in Canada?

Often yes — the same drug is frequently cheaper in Canada because the Canadian government negotiates prices. However, importing drugs from Canada into the United States is technically illegal, though enforcement is rare for personal use. Talk to your doctor about generic alternatives or information programs before considering this option.

Will the new negotiation power in the 2023 law bring drug prices down for everyone?

It will affect only the drugs on the negotiation list, which is small and grows slowly. For those drugs, prices may come down over time as Medicare negotiates. But the vast majority of drugs remain under the 2003 ban. Broader price reductions would require Congress to change the law further.